leisure time -WSS

leisure time

author：knowledge 2025-10-02 04:08:11 - browse：4

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

WSS

Ambulance rides for just $100? Advisers want major billing fixes

Obesity drugs seen as possible treatment for liver disease MASH

Antivenom research: Lessons from HIV applied in search for universal antidote

A solution to the after

In utero gene editing: an explainer

A solution to the after

hotspot

leisure time

knowledge

Continuity nursing helped my family in our darkest PICU moments

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Jerome Adams on the need for new antivirals for Covid

10 million people disenrolled from Medicaid over past six months

Peter Hotez and the public health issue of online harassment

Abortion clinic in Cancun will cater to Americans

Medicare details structure of new drug price negotiation program

6 phony surgeries that take placebo to the extreme

New air purifier tech could be key to improving indoor air quality

Ambulance rides for just $100? Advisers want major billing fixes

leisure time

10 million people disenrolled from Medicaid over past six months

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Ambulance rides for just $100? Advisers want major billing fixes

Medicare will require more price transparency from hospitals

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

STAT readers on older presidents, polypills, Medicare, and more

entertainment

entertainment

hotspot

explore